Brigatinib granted priority review and orphan drug status.
-
FDA approves brigatinib for ALK-positive mNSCLC -
The study forms a part of the TRACERx initiative.
-
Lung cancer: 1 in 5 develop pemetrexed-related nephrotoxicity Risk increases with longer treatment duration.
-
NICE Recommends Atezolizumab for Extensive-stage Small Cell Lung Cancer NICE has reversed another decision on atezolizumab after getting a better NHS discount.
-
Nivolumab plus ipilimumab for mNSCLC wins FDA approval Combination therapy received priority review and fast-track status
-
NICE recommends lorlatinib for metastatic ALK-positive NSCLC Approval based on indirect analyses of lorlatinib with chemotherapy.
-
ASCO 2020 – Lung cancer: Quitting smoking at any point boosts OS Even smokers who quite less than 2 years before diagnosis saw a significant survival boost
-
NICE approves lorlatinib for ALK-positive advanced NSCLC Lorlatinib for previously treated ALK-positive advanced non-small cell lung cancer.
-
FDA approves selpercatinib for RET-driven lung and thyroid cancers The accelerated approval was based on LIBRETTO-001 trial.
-
NSCLC: low-dose erlotinib shows benefit in older patients with frailty Little is known about EGFR-TKI efficacy in this patient population.
-
NSCLC surgery after neoadjuvant atezolizumab, chemotherapy Almost 90% of patients had R0 resection after neoadjuvant treatment.
-
Lung cancer: exposure to diesel engine exhaust hikes risk Occupational exposure at any level raised risk in men.
-
NICE approves two new cancer treatments New treatments for relapsed follicular lymphoma and ALK-positive advanced NSCLC
-
FDA approves capmatinib and companion assay for metastatic NSCLC The approval was based on the phase 2 GEOMETRY mono-1 trial.